The Long and Winding Road to Effective Immunotherapy in Patients with Adrenocortical Carcinoma
2020; Future Medicine; Volume: 16; Issue: 36 Linguagem: Inglês
10.2217/fon-2020-0686
ISSN1744-8301
AutoresSalvatore Grisanti, Deborah Cosentini, Marta Laganà, Alberto Dalla Volta, Carlotta Palumbo, Guido Alberto Massimo Tiberio, Sandra Sigala, Alfredo Berruti,
Tópico(s)Cancer Immunotherapy and Biomarkers
ResumoFuture OncologyVol. 16, No. 36 EditorialThe long and winding road to effective immunotherapy in patients with adrenocortical carcinomaSalvatore Grisanti, Deborah Cosentini, Marta Laganà, Alberto Dalla Volta, Carlotta Palumbo, Guido Alberto Massimo Tiberio, Sandra Sigala & Alfredo BerrutiSalvatore Grisanti *Author for correspondence: E-mail Address: grisanti.salvatore@gmail.comhttps://orcid.org/0000-0001-6922-1934Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia, 25123, Italy, Deborah CosentiniMedical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia, 25123, Italy, Marta LaganàMedical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia, 25123, Italy, Alberto Dalla Volta https://orcid.org/0000-0001-8009-7663Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia, 25123, Italy, Carlotta Palumbo https://orcid.org/0000-0002-6165-5276Urology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia, 25123, Italy, Guido Alberto Massimo Tiberio https://orcid.org/0000-0002-7635-1179Surgical Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia, 25123, Italy, Sandra Sigala https://orcid.org/0000-0003-3294-4121Department of Molecular & Translational Medicine, Section of Pharmacology, University of Brescia, Brescia, 25123, Italy & Alfredo Berruti https://orcid.org/0000-0002-3956-0043Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia, 25123, ItalyPublished Online:28 Aug 2020https://doi.org/10.2217/fon-2020-0686AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: Adrenocortical carcinomahypercortisolismimmune checkpoints inhibitorsimmunogenicityimmunotherapyPD-L1progression-free survivaltumor infiltrating lymphocytesReferences1. Terzolo M, Daffara F, Ardito A et al. Management of adrenal cancer: a 2013 update. J. Endocrinol. Invest. 37(3), 207–217 (2014).Crossref, Medline, CAS, Google Scholar2. Grisanti S, Cosentini D, Laganà M et al. Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures. Curr. Opin. Endocr. Metab. Res. 8, 80–87 (2019).Crossref, Google Scholar3. Bonneville R, Krook MA, Kautto EA et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis. Oncol. 1, PO.17.00073 (2017).Google Scholar4. Le DT, Durham JN, Smith KN et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409–413 (2017).Crossref, Medline, CAS, Google Scholar5. Chang LS, Barroso-Sousa R, Tolaney SM et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40(1), 17–65 (2019).Crossref, Medline, Google Scholar6. Tierney JF, Vogle A, Poirier J et al. Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: an exploratory study. Surgery 165(1), 196–201 (2019).Crossref, Medline, Google Scholar7. Brabo EP, Moraes AB, Neto LV. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. J. Endocrinol. Invest. 43(11), 1531–1542 (2020).Crossref, Medline, CAS, Google Scholar8. Le Tourneau C, Hoimes C, Zarwan C et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial. J. Immunother. Cancer. 6(1), 111 (2018).Crossref, Medline, Google Scholar9. Habra MA, Stephen B, Campbell M et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J. Immunother. Cancer. 7(1), 253 (2019).Crossref, Medline, Google Scholar10. Raj N, Zheng Y, Kelly V et al. PD-1 blockade in advanced adrenocortical carcinoma. J. Clin. Oncol. 38(1), 71–80 (2020).Crossref, Medline, CAS, Google Scholar11. Carneiro B, Konda B, Costa RB et al. Nivolumab in metastatic adrenocortical carcinoma: results of a Phase 2 trial. J. Clin. Endocrinol. Metab. 104(12), 6193–6200 (2019).Crossref, Medline, Google Scholar12. Fojo AT. Immunotherapy for adrenocortical cancer. Semin. Oncol. 46(1), 1–2 (2019).Crossref, Medline, Google Scholar13. Henning JEK, Deutschbein T, Altieri B et al. Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J. Clin. Endocrinol. Metab. 102(11), 4323–4332 (2017).Crossref, Medline, Google Scholar14. Cosentini D, Badalamenti G, Grisanti S et al. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur. J. Endocrinol. 181(6), 681–689 (2019).Crossref, Medline, CAS, Google Scholar15. Ambrosini R, Balli MC, Laganà M et al. Adrenocortical carcinoma and CT assessment of therapy response: the value of combining multiple criteria. Cancers 12(6), 1395 (2020).Crossref, CAS, Google Scholar16. Cosentini D, Grisanti S, Dalla Volta A et al. Immunotherapy failure in adrenocortical cancer: where next? Endocr. Connect. 7(12), E5–E8 (2018).Crossref, Medline, CAS, Google Scholar17. Fiorentini C, Grisanti S, Cosentini D et al. Molecular drivers of potential immunotherapy failure in adrenocortical carcinoma. J. Oncol. 2019, 6072863 (2019).Crossref, Medline, Google Scholar18. Zheng S, Cherniack AD, Dewal N et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29(5), 723–736 (2016).Crossref, Medline, CAS, Google Scholar19. Landwehr LS, Altieri B, Schreiner J et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J. Immunother. Cancer. 8(1), e000469 (2020).Crossref, Medline, Google Scholar20. Wang S, He Z, Wang X et al. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. eLife. 8, e49020 (2019).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByEndocrine and Neuroendocrine Tumors: A Special Issue12 October 2022 | Cancers, Vol. 14, No. 20Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen14 May 2022 | Endocrine, Vol. 77, No. 3Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinomaESMO Open, Vol. 7, No. 2Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells7 December 2021 | Endocrinology, Vol. 163, No. 2Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review20 September 2021 | Frontiers in Immunology, Vol. 12Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer26 April 2021 | Frontiers in Endocrinology, Vol. 12Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma22 April 2021 | Frontiers in Endocrinology, Vol. 12 Vol. 16, No. 36 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 134 times History Received 5 July 2020 Accepted 4 August 2020 Published online 28 August 2020 Published in print December 2020 Information© 2020 Future Medicine LtdKeywordsAdrenocortical carcinomahypercortisolismimmune checkpoints inhibitorsimmunogenicityimmunotherapyPD-L1progression-free survivaltumor infiltrating lymphocytesAuthor contributionsS Grisanti was responsible for conceptualization, data interpretation and writing. D Cosentini, M Laganà AD Volta and C Palumbo handled data acquisition. GAM Tiberio and S Sigala provided data interpretation and critical review. A Berruti was responsible for conceptualization, data interpretation and critical review.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)